Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
The obesity paradox, where obesity appears to confer a protective effect, was noted in metastatic castration-resistant prostate cancer (CRPC), with improved survival outcomes among obese patients with metastatic CRPC, according to a study from EAU21.
In prostate cancer (PC) patients undergoing hormone therapy, the development of lifestyle-related disorders, particularly diabetes mellitus (DM), predicts an earlier progression to castration-resistant PC (CRPC) and poor prognosis, a recent study has found.
Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.
Injecting a hydrogel spacer is useful for putting some distance between the rectum and prostate during radiotherapy for prostate cancer, a study reports. As a result, radiation exposure in the rectum is minimized, and late gastrointestinal and genitourinary toxicities are reduced.
Final analysis of the phase III TITAN* trial, presented at ASCO GU 2021, has shown that the addition of apalutamide to androgen deprivation therapy (ADT) improves overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC).